Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Flamel Technologies names new chief business officer
Mr Vick previously served as CEO of Silence Therapeutics, a European RNAi company. He received his MBA from Stanford University, his MS in chemistry from the University of
Mr Vick previously served as CEO of Silence Therapeutics, a European RNAi company. He received his MBA from Stanford University, his MS in chemistry from the University of
During the research phase of the collaboration, Xencor will provide CSL with the opportunity to utilize the technology broadly across its antibody candidate pipeline. Xencor has granted CSL
Dr Dhingra is currently heading KAPital Consulting, a company engaged in helping biotechnology, pharmaceutical and diagnostic companies realize the clinical and commercial promise of the advances in oncology.
The agreement will involve co-operation in joint marketing and promotional activities and the integration of PreViser analytic technology into MacPractice DDS 3.6, making MacPractice the only native Mac-compatible
This agreement is expected to provide the physicians greater choice and flexibility in offering patients the newest isotope available. According to IsoRay, the Cesium-131 seed offers a significantly
According to Cordex, the amendment addresses written comments recently received from the FDA in response to the company’s initial special protocol assessment (SPA) submission to the FDA in
The objectives of the trial include assessment of safety, tolerability and pharmacokinetics. ABT-450 was discovered as part of a worldwide alliance between Abbott and Enanta to discover, develop
The CE mark makes it possible for cancer treatment centers to begin ordering, installing, and using the Varian proton therapy system in regions where CE mark is required
The Phase IIa study is designed to assess the efficacy, safety, tolerability and pharmacokinetics of ALKS 27 in approximately 24 patients with chronic obstructive pulmonary disease (COPD). In
Net loss for the fourth quarter of 2008 includes total stock-based compensation expense of $3.7 million, compared to $1.8 million for the fourth quarter of 2007. For the